Novartis Scores Another CSU Success With Remibrutinib
Oral BTK Inhibitor Controls Itching And Hives In Phase IIb
The Swiss group believes that remibrutinib, as well as its investigational IgE antibody ligelizumab, will complement standard of care Xolair and help it build a strong franchise for chronic spontaneous urticaria.
